KISSEI's History

Aug. 1946 Founded as Tachibana Seikagaku Institute Co., Ltd.
May. 1947 Corporate name changed to Kissei Yakuhin Kogyo Co., Ltd.
Dec. 1961 GASCON, a gastrointestinal anti-gas agent, launched.
Oct. 1964 Corporate name changed to Kissei Pharmaceutical Co., Ltd.
Head Office and factories constructed at present location.
May 1969 Central Research Laboratories constructed.
Apr. 1973 Central Research Laboratories expanded.
Jul. 1980 Manufacturing Plant constructed.
Aug. 1982 RIZABEN, a drug for the treatment of allergic diseases, launched.
Jun. 1985 Toxicological Laboratories constructed.
May 1986 Manufacturing Plant expanded.
Aug. 1986 UTEMERIN, a drug for threatened premature labor and threatened abortion, launched.
Apr. 1988 XANBON, a drug for cerebral circulation improvement, launched.
Dec. 1988 Company listed on the Second Section of the Tokyo Stock Exchange.
Apr. 1990 Foodstuff Business Unit established.
Nov. 1990 Central Research Laboratories moved.
Dec. 1990 Shiojiri Distribution Center constructed.
Apr. 1991 BEZATOL, a drug for the treatment of hyperlipidemia, launched.
Sep. 1991 Company listed on the First Section of Tokyo Stock Exchange.
Dec. 1991 Kissei Information Center constructed.
May 1992 FRAGMIN, an anti-coagulant, launched.
Jun. 1992 DOMENAN, for the treatment of bronchial asthma, launched.
May 1993 Matsumoto Third Drug Manufacturing Plant constructed.
Oct. 1994 Shiojiri Plant constructed.
Jul. 1995 Tokyo Head Office established.
Nov. 1995 Wholly owned Sendai Branch building constructed.
First Quality Control Laboratory constructed.
Dec. 1995 RIZABEN Eye Drops, for the treatment of allergic conjunctivitis, launched.
Aug. 1996 50th anniversary of the company's founding.
Sep. 1996 Pharmaceutical Laboratories constructed.
Dec. 1996 History of Kissei's 50 Years compiled.
Mar. 1997 Tokyo Head Office(Koishikawa) established.
Oct. 1997 Kissei Pharma U.S.A., Inc. subsidiary established.
Des. 1997 Wholly owned Sapporo Branch building constructed.
May 1999 Toxicological Laboratories expanded.
Aug. 1999 CABASER, a drug for the treatment of Parkinson's disease, launched.
Nov. 1999 RYSMON TG Ophthalmic Solution, a drug for the treatment of glaucoma and ocular hypertension, launched.
Dec. 1999 Environmental directive established.
Oct. 2000 ZOLADEX 1.8mg, a dug for the treatment of endometriosis, launched.
May 2001 Nutritional Business Center constructed.
Aug. 2001 FULSTAN, an active vitamin D3 preparation, launched.
Apr. 2004 U.S.-based companies reorganized, Kissei America, Inc. established.
May 2004 GLUFAST, a drug for the treatment of type 2 diabetes, launched.
Sep. 2005 SALAGEN, a drug for the treatment of xerostomia, launched.
May 2006 URIEF, a drug for the treatment of dysuria associated with benign prostatic hyperplasia, launched.
Feb. 2007 Central Research Laboratories expanded.
Apr. 2007 Joetsu Chemical Laboratories constructed.
Apr. 2009 Silodosin (brand name in Japan : URIEF ), a drug for the treatment of dysuria associated with benign prostatic hyperplasia, launched in the US.
Apr. 2010 New main building of Matsumoto head office constructed.
May 2010 EPOETIN ALFA BS Injection, a drug for the renal anemia, launched.